Trinity Biotech PLC
TRIB- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000888721
No open-market purchases or sales by Trinity Biotech PLC insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $379.5K in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Trinity Biotech PLC changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 29 | 23 | −6 |
| Shares | 5.66M | 5.52M | −148.8K (−2.6%) |
| Value | $16.6M | $11.9M | −$4.74M (−28.5%) |
New holders (3)
Institutions that held Trinity Biotech PLC at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 64,424 | $139.0K | 0.00% |
| Ground Swell Capital, LLC | 10,981 | $24.0K | 0.10% |
| JPMorgan Chase & Co | 2 | $0 | 0.00% |
Sold out (9)
Institutions that held Trinity Biotech PLC at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Susquehanna Fundamental Investments, LLC | 33,416 | $98.0K |
| Geode Capital Management, LLC | 13,909 | $40.0K |
| Two Sigma Securities, LLC | 11,723 | $34.0K |
| Two Sigma Investments, LP | 11,095 | $33.0K |
| Goldman Sachs Group Inc | 10,937 | $32.0K |
| Two Sigma Advisers, LP | 10,300 | $30.0K |
| Northern Trust Corp | 4,399 | $13.0K |
| Huntington National Bank | 4,000 | $12.0K |
| Advisor Group Holdings, Inc. | 2,109 | $6.00K |